The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
EHA2023 abstracts: What’s hot in MDS?
To help navigate the exciting content being presented at the European Hematology Association (EHA) 2023 Congress, the MDS Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MDS.
Friday, June 9
Saturday, June 10
|
Abstract |
Type |
Title |
Presenter |
|---|---|---|---|
|
S102 |
Plenary session |
Luspatercept versus epoetin alfa for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions: data from the phase 3 commands study |
Matteo Giovanni Della Porta |
|
S164 |
Oral presentation |
Disease modifying activity of imetelstat in patients with heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3 |
Valeria Santini |
|
S172 |
Oral presentation |
Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia |
Alex Bataller |
|
S173 |
Oral presentation |
Elena Crisà |
|
|
S174 |
Oral presentation |
Lisa Pleyer |
|
|
s265 |
SWG session |
Myelodysplastic syndromes: myelodysplastic neoplasms given the new WHO classification |
Chair: Uwe Platzbecker |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content